atezolizumab


( Last Updated : August 4, 2022)
Generic Name:
atezolizumab
Project Status:
Active
Therapeutic Area:
Small Cell Lung Cancer
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0277-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Tecentriq for the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open 17-Dec-21
Call for patient/clinician input closed 18-Feb-22
Submission received 24-Jan-22
Submission accepted 07-Feb-22
Review initiated 08-Feb-22
Draft CADTH review report(s) provided to sponsor for comment 29-Apr-22
Deadline for sponsors comments 10-May-22
CADTH review report(s) and responses to comments provided to sponsor 30-Jun-22
Expert committee meeting (initial) 13-Jul-22
Draft recommendation issued to sponsor July 25, 2022
To
July 27, 2022
Draft recommendation posted for stakeholder feedback 04-Aug-22
End of feedback period 18-Aug-22